Intellia Therapeutics’ rare genetic disorder therapy meets main goal in trial

April 27 (Reuters) – ​Intellia ‌Therapeutics said ‌on ​Monday ⁠its ⁠experimental therapy for ​a ⁠rare ⁠genetic ​disorder ​has met ‌the ⁠main goal in ⁠a ‌late-stage ⁠study.

(Reporting ​by ‌Kunal ​Das; Editing ⁠by Vijay ​Kishore)